Related Experiment Video
Updated: May 22, 2026
12:23
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
[Biomarkers in neuromyelitis optica]
Tatsuro Misu1, Toshiyuki Takahashi, Ichiro Nakashima
1Department of Neurology, Tohoku University Graduate School of Medicine, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 10, 2012
Summary
Neuromyelitis optica (NMO) is diagnosed using autoantibodies targeting aquaporin-4 (AQP4). Cerebrospinal fluid biomarkers like GFAP indicate astrocytic damage, aiding NMO diagnosis and differentiating it from multiple sclerosis (MS).
Area of Science:
- Neuroimmunology
- Autoimmune diseases
- Biomarker discovery
Context:
- Neuromyelitis optica (NMO) is an autoimmune disorder targeting the central nervous system.
- The NMO-IgG autoantibody targets aquaporin-4 (AQP4), primarily found in astroglial foot processes.
- Current diagnostic methods for NMO include cell-based assays detecting AQP4 antibodies.
Purpose:
- To review and highlight key biomarkers for diagnosing NMO and NMO spectrum disorders.
- To discuss the role of autoantibodies, inflammatory markers, and astrocyte damage indicators in NMO.
- To evaluate the diagnostic utility of cerebrospinal fluid (CSF) analysis in NMO.
Summary:
- NMO-IgG autoantibody targeting aquaporin-4 (AQP4) is a key diagnostic marker for NMO.
- Cerebrospinal fluid (CSF) analysis reveals pleocytosis, elevated IgG index, and specific cytokines (IL-17, IL-6, BAFF) indicative of inflammation and lesion formation.
- Increased CSF glial fibrillary acidic protein (GFAP) levels signify astrocytic damage, distinguishing NMO from multiple sclerosis (MS).
Impact:
- Improved diagnostic accuracy for NMO and NMO spectrum disorders.
- Potential for earlier and more precise diagnosis through biomarker assessment.
- Enhanced understanding of NMO pathogenesis and inflammatory mechanisms.
